

Selected BIO-X Accelerate companies



ArgusEye

In an industry heavily dependent on manual testing performed far away from the production ArgusEye aims to accelerate the development and production of some of our most important medicines, biologics, with real-time in-line analytics. With some of the world's largest pharmaceutical companies as its customers ArgusEye's aims further strengthens its offering through BIO-X Accelerate with a sensor system that provides protein specific data in-line during the cell culture (upstream production) of biologics.

Phenaros Pharmaceuticals

Phenaros develops a platform based on AI and automation to accelerate drug discovery. Our platform enables detailed studies of cells, and our robotized laboratory ensures scalable and reproducible data of the highest quality. Combined with modern AI, we achieve higher accuracy than current methods on the market, leading to improved decision-making and thereby better properties of drug candidates, reduced costs, and faster discoveries. The platform is based on many years of research at Uppsala University, is disease-agnostic, and therefore globally applicable. We are currently validating our platform and business model in collaboration with large international pharmaceutical companies, as well as local biotech ones. Our next steps will include establishing a dedicated lab and accelerate our activities.

Rarity Bioscience

Rarity is committed to the clinical unmet need of minimal/measurable residual disease, meaning monitoring mutations using liquid biopsies during and after cancer treatment to detect any residual or relapsing mutations. This mechanism exist across all cancers and Rarity is active in both leukaemia as well as several solid tumour cancers. Rarity has developed the superRCA technology, an assay platform for nucleic acid analysis that detect mutations with a sensitivity 10-100 times higher than current gold standard. The assays also enables multiplex analysis and utilizes IVD certified flow cytometers for the readout, meaning that the instruments needed are already available in the labs. There are several ongoing collaborations with leading researchers across several cancers, as well as services for pharmaceutical clients. The company are currently setting up production to start sell products/kits for external use during 2024.

Readily Diagnostics

Readily Diagnostics' goal is to make diagnostics readily available. We develop a new generation rapid diagnostic platform for infectious disease, starting with respiratory disease. Our tests will bring laboratory quality tests to the bedside, and enabling sensitive near-patient testing for urgent care.

Strike Pharma

Enhancing drug efficacy and safety hinges on targeted delivery methods, with RNA-based therapeutics now advancing into clinical application through formulation into liponanoparticles (LNPs) for stability and cellular absorption. The next frontier lies in refining organ or cell-specific targeting, achieved through antibody-based strategies to ferry RNA therapeutics, thus revolutionizing their use as drugs. This project endeavors to advance such developments through the utilization of the Adaptable Drug Affinity Conjugate (ADAC) technology. Ultimately, we aim to facilitate targeted drug delivery within the field of precision medicine.



Bonus pitches from BIO-X Accelerate applicants

Cellda AB

Cellda AB has developed a platform meeting an increasing demand for digital pathology and tools to standardize and streamline cancer diagnoses. The first product Cellda® Prostate will assist pathologists to detect cancer during the review of images from prostate needle biopsies prepared from immunohistochemistry (IHC) stained tissue resulting in more effective handling and enhanced confidence in prostate cancer diagnosis benefiting both patients and healthcare providers.

Extem Pharma

This project will establish a testbed for 3D printed precision medicines for better and safer treatments of humans and animals. We will establish a laboratory for formulation design and 3D printing to enable production of oral medications of 'difficult to deliver' compounds. The setting also provides a unique small batch production to enable a larger number of clinical trials to take place in Swedish hospitals and veterinary clinics.

MyCural Therapeutics

We aim to revolutionize drug discovery paradigms by leveraging AI to address the challenges associated with targeting intrinsically disordered proteins, such as the oncoprotein MYC, which is implicated in over half of all cancers. This approach has the potential to accelerate the development of anti-MYC therapies

Oxlantic Medical AB

Oxlantic Medical's business idea is to develop the world's first truly wearable capnography solution, based on MARIE – our Mainstream Respiratory Infrared Equipment. Customers will be international medical device companies integrating Oxlantic Medical's capnography technology as an OEM product into their equipment for use in hospitals, emergency care and the untapped homecare market. The global capnography market, homecare not included, is growing at a CAGR of 10% and is estimated to reach 1450 MEUR in 2030.

Stardots

Stardots, Inc is a US entity and a subsidiary of Stardots AB which is a private company located in Uppsala, Sweden. Stardots specializes in the development of software as a medical device (SaMD) using advanced mathematical modelling of sensor data. We are focusing on digital biomarkers and treatment optimization for neurology and psychiatry with a special focus on Parkinson's disease and autism diagnosis.

Thursday, September 12th

Time: 15:00-19:00

Location: Kungsgatan 36A (Bjerking, 7th floor)

[Register here](#)